SOURCE-LINKED STUDY SUMMARY
Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial.
Full paper summarizedQuality not appraised
- What was studied
- Double-blind randomized trial of bimagrumab added to optimized nutrition and exercise for sarcopenia; primary outcome was physical performance.
- Who / model studied
- 180 community-dwelling adults aged ≥70 with sarcopenia: 113 bimagrumab and 67 placebo; 159 completed.
- Studied dose & schedule
- Bimagrumab 700 mg intravenously every 4 weeks for 24 weeks versus placebo; both groups received nutrition support, vitamin D and home exercise.
- What the study found
- Lean mass rose 2.02 versus 0.08 kg. Physical-performance scores improved 1.34 versus 1.03 points (P=.13), without significant walking benefit. Muscle spasms occurred in 32.7 versus 14.9 percent; diarrhea in 19.5 versus 3.0 percent.
- Limitations & context
- More DXA lean mass did not establish better strength or mobility. Optimized background care and an unbalanced racial distribution limit generalization; long-term safety was not established.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: full paper. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1001/jamanetworkopen.2020.20836